-
Je něco špatně v tomto záznamu ?
Anti-inflammatory effect of fluvastatin on polarized macrophages and its dependence on the mevalonate pathway
B. Muffova, S. Kauerova, K. Paukner, H. Bartuskova, R. Poledne, I. Kralova Lesna
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
LX22NPO5104
European Union - Next Generation EU
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2021-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2021-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
Springer Nature - nature.com Journals - Fully Open Access
od 2011-12-01
- MeSH
- antiflogistika * farmakologie MeSH
- cytokiny metabolismus MeSH
- fluvastatin * farmakologie MeSH
- kyselina mevalonová * metabolismus MeSH
- lidé MeSH
- makrofágy * účinky léků metabolismus imunologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
The study focuses on the effects of fluvastatin on immunomarkers of the M1 and M2 macrophages and its direct role in macrophage (M0) polarization. Moreover, it investigates the dependency of immunomodulatory properties of fluvastatin on the mevalonate pathway. Macrophages (M0, M1, M2), differentiated from human blood monocytes, were treated with fluvastatin. Mevalonate and geranylgeranyl pyrophosphate intermediates were introduced to assess the mevalonate pathway dependence. The immunomarkers were evaluated with qPCR, ELISA, Griess assay, and flow cytometry. Fluvastatin significantly reduces the pro-inflammatory gene expression (NFκB, IL-1β, IL-6, iNOS) in M1 while enhancing the anti-inflammatory markers (Arg-1, TGFβ) in M2 macrophages. The production of the TNFα, IL-1β, and IL-6 cytokines is reduced in M1, and IL-10 production increased in M2 macrophages. Fluvastatin decreases the iNOS activity in M1 macrophages. The intermediates reverse the fluvastatin's effects on anti-inflammatory gene expression by M2 macrophages, cytokine production (by M1 and M2 macrophages), and iNOS activity (by M1 macrophages). Their impact on surface marker expression was somewhat limited. These findings demonstrate that fluvastatin exerts anti-inflammatory effects on polarized macrophages without affecting polarization per se and also highlight the dependency on the mevalonate pathway. This study deepens the understanding of statins' immunomodulatory mechanisms, suggesting potential applications in treating inflammatory diseases.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015390
- 003
- CZ-PrNML
- 005
- 20250731090941.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-025-02418-9 $2 doi
- 035 __
- $a (PubMed)40456744
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Muffova, Barbora $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. mufb@ikem.cz $u Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic. mufb@ikem.cz
- 245 10
- $a Anti-inflammatory effect of fluvastatin on polarized macrophages and its dependence on the mevalonate pathway / $c B. Muffova, S. Kauerova, K. Paukner, H. Bartuskova, R. Poledne, I. Kralova Lesna
- 520 9_
- $a The study focuses on the effects of fluvastatin on immunomarkers of the M1 and M2 macrophages and its direct role in macrophage (M0) polarization. Moreover, it investigates the dependency of immunomodulatory properties of fluvastatin on the mevalonate pathway. Macrophages (M0, M1, M2), differentiated from human blood monocytes, were treated with fluvastatin. Mevalonate and geranylgeranyl pyrophosphate intermediates were introduced to assess the mevalonate pathway dependence. The immunomarkers were evaluated with qPCR, ELISA, Griess assay, and flow cytometry. Fluvastatin significantly reduces the pro-inflammatory gene expression (NFκB, IL-1β, IL-6, iNOS) in M1 while enhancing the anti-inflammatory markers (Arg-1, TGFβ) in M2 macrophages. The production of the TNFα, IL-1β, and IL-6 cytokines is reduced in M1, and IL-10 production increased in M2 macrophages. Fluvastatin decreases the iNOS activity in M1 macrophages. The intermediates reverse the fluvastatin's effects on anti-inflammatory gene expression by M2 macrophages, cytokine production (by M1 and M2 macrophages), and iNOS activity (by M1 macrophages). Their impact on surface marker expression was somewhat limited. These findings demonstrate that fluvastatin exerts anti-inflammatory effects on polarized macrophages without affecting polarization per se and also highlight the dependency on the mevalonate pathway. This study deepens the understanding of statins' immunomodulatory mechanisms, suggesting potential applications in treating inflammatory diseases.
- 650 12
- $a fluvastatin $x farmakologie $7 D000077340
- 650 12
- $a kyselina mevalonová $x metabolismus $7 D008798
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a makrofágy $x účinky léků $x metabolismus $x imunologie $7 D008264
- 650 12
- $a antiflogistika $x farmakologie $7 D000893
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kauerova, Sona $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Paukner, Karel $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Bartuskova, Hana $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Poledne, Rudolf $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Kralova Lesna, Ivana $u Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Anesthesia and Intensive Medicine, First Faculty of Medicine, Charles University and University Military Hospital, Prague, Czech Republic
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 15, č. 1 (2025), s. 19237
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40456744 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090935 $b ABA008
- 999 __
- $a ok $b bmc $g 2366307 $s 1252515
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 15 $c 1 $d 19237 $e 20250602 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a LX22NPO5104 $p European Union - Next Generation EU
- LZP __
- $a Pubmed-20250708